A prospective, randomized study comparing different therapeutic modalities for acute adenoviral conjunctivitis.

Indian J OphthalmolAug 24, 2026 (epub)
Clinical ResearchOphthalmology

Anchal Thakur, Surya P Sharma, Poonam Chauhan et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective randomized study evaluated the effectiveness of three therapeutic modalities for acute adenoviral conjunctivitis in 65 patients. The combination of Povidone-iodine (PVP-I) 1% and ganciclovir 0.15% with dexamethasone 0.1% significantly improved symptoms such as foreign body sensation, pain, and conjunctival congestion at day 7 compared to other treatments.

Key findings

  • Group 3 showed significantly better outcomes for foreign body sensation (P = 0.013) at day 7.
  • Pain was significantly reduced in Group 3 compared to others (P = 0.019) at day 7.
  • Conjunctival congestion was significantly lower in Group 3 (P = 0.00) at day 7.
  • The control group had significantly more subepithelial infiltrates (P = 0.0001) at day 7.

Why it matters

Understanding effective treatment options for acute adenoviral conjunctivitis is crucial for improving patient outcomes. This study highlights the potential benefits of combining antiviral and anti-inflammatory therapies.

Source

PubMed · PMID 42635492

Published in Indian J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.